[B01AD01, streptokinase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Streptokinase.]
[B02AB01, aprotinin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin.]
[B02AA02, tranexamic acid, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.]
[L01XF01, tretinoin, The risk or severity of Thrombosis can be increased when Tretinoin is combined with Alpha-1-proteinase inhibitor.]
[B01AD04, urokinase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Urokinase.]
[B02AA03, 4-aminomethylbenzoic acid, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminomethylbenzoic acid.]
[B02BX06, emicizumab, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Emicizumab.]
[V03AB38, andexanet alfa, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Andexanet alfa.]
[B01AD11, tenecteplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Tenecteplase.]
[B02BD03, anti-inhibitor coagulant complex, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).]
[B01AD03, anistreplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Anistreplase.]
[B02BD08, factor VIIa, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Catridecacog.]
[B02BD07, factor XIII, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human).]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.]
[S02AA06, hydrogen peroxide, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Hydrogen peroxide.]
[C04AF01, kininogenase, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Kallidinogenase.]
[B02BA02, vitamin K3, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione.]
[B01AD07, reteplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Reteplase.]
[S01XA13, alteplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Alteplase.]
[B02AA01, 6-aminocaproic acid, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid.]
[B01AD01, streptokinase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Streptokinase.]
[B02AB01, aprotinin, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aprotinin.]
[B02AA02, tranexamic acid, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Tranexamic acid.]
[L01XF01, tretinoin, The risk or severity of Thrombosis can be increased when Tretinoin is combined with Alpha-1-proteinase inhibitor.]
[B01AD04, urokinase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Urokinase.]
[B02AA03, 4-aminomethylbenzoic acid, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminomethylbenzoic acid.]
[B02BX06, emicizumab, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Emicizumab.]
[V03AB38, andexanet alfa, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Andexanet alfa.]
[B01AD11, tenecteplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Tenecteplase.]
[B02BD03, anti-inhibitor coagulant complex, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor IX Complex (Human).]
[B01AD03, anistreplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Anistreplase.]
[B02BD08, factor VIIa, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.]
[B02BD14, antihemophilic factor, porcine B-domain truncated recombinant, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Susoctocog alfa.]
[B02BD11, coagulation factor XIII a-subunit (recombinant), Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Catridecacog.]
[B02BD07, factor XIII, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Factor XIII (human).]
[B02BB01, fibrinogen, human, The therapeutic efficacy of Fibrinogen human can be increased when used in combination with Alpha-1-proteinase inhibitor.]
[S02AA06, hydrogen peroxide, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Hydrogen peroxide.]
[C04AF01, kininogenase, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Kallidinogenase.]
[B02BA02, vitamin K3, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Menadione.]
[B01AD07, reteplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Reteplase.]
[S01XA13, alteplase, The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Alteplase.]
[B02AA01, 6-aminocaproic acid, Alpha-1-proteinase inhibitor may increase the thrombogenic activities of Aminocaproic acid.]
